{"entity":{"id":"juniper-biosciences","kind":"company","name":"Juniper Biosciences","aka":["Juniper Radiopharma"],"tldr":"Juniper Biosciences develops radioactive scan agents and treatments for cancer. Its most advanced product is a PET tracer that shows low-oxygen areas in HPV-positive head and neck cancers, which could help doctors tailor radiotherapy.","summary":"Juniper Biosciences LLC is a New Jersey radiopharmaceutical company developing diagnostic and therapeutic agents for oncology. It announced an oversubscribed, upsized USD 40 million seed financing on 1 December 2025 through its parent Juniper Radiopharma LLC, co-led by NovaCapital, high-net-worth individuals and members of the Club degli Investitori; Alex Agnoletto is CEO. Its pipeline lists JBS-003 (F-MISO, fluorine-18 fluoromisonidazole) for imaging hypoxic tumour cells in HPV-positive head and neck cancer, which the company says has FDA Breakthrough Therapy Designation; JBS-002, a gallium-68 PSMA agent; JBS-004, a fluorine-18 tracer for Alzheimer's disease; and JBS-005, undisclosed alpha, beta and gamma emitter programmes.","asOf":"2026-10-29","links":[{"label":"Official website","url":"https://juniperbiosci.com/"},{"label":"Seed financing release (republished by Santelog)","url":"https://www.santelog.com/actualites-sante-nasdaq/juniper-biosciences-raises-oversubscribed-and-upsized-40-million-seed"}],"tags":[],"related":[],"cancers":["hpv-positive-oropharyngeal-cancer","head-and-neck","prostate"],"sections":["radiopharma"],"technologies":["tumour-hypoxia-modification","psma-pet","pet"],"targets":["psma"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Founding year not stated. The seed release gives Bridgewater, NJ; the website now gives a Bedminster, NJ address. The Breakthrough Therapy Designation for JBS-003 is stated on the company website and was not checked against an FDA source. Stages of the pipeline programmes could not be read from the website."],"hq":"Bedminster, NJ","country":"US","companyType":"radiopharma","website":"https://juniperbiosci.com/","stage":"startup","investors":[],"funding":[{"round":"Seed","year":2025,"amountUsd":40000000,"source":"https://www.santelog.com/actualites-sante-nasdaq/juniper-biosciences-raises-oversubscribed-and-upsized-40-million-seed"}]},"route":"/companies/juniper-biosciences/","neighbours":{"cancer":[{"id":"head-and-neck","kind":"cancer","name":"Head and neck squamous cell carcinoma","route":"/cancers/head-and-neck/"},{"id":"hpv-positive-oropharyngeal-cancer","kind":"cancer","name":"HPV-positive oropharyngeal cancer","route":"/cancers/hpv-positive-oropharyngeal-cancer/"},{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"}],"section":[{"id":"radiopharma","kind":"section","name":"Radiopharmaceuticals & Theranostics","route":"/fronts/radiopharma/"}],"technology":[{"id":"pet","kind":"technology","name":"PET (positron emission tomography)","route":"/technologies/pet/"},{"id":"psma-pet","kind":"technology","name":"PSMA PET","route":"/technologies/psma-pet/"},{"id":"tumour-hypoxia-modification","kind":"technology","name":"Tumour hypoxia: imaging and modification","route":"/technologies/tumour-hypoxia-modification/"}],"target":[{"id":"psma","kind":"target","name":"PSMA","route":"/targets/psma/"}]}}